Transitional cell carcinoma of the urothelial tract

Active Ingredient: Vinflunine

Indication for Vinflunine

Population group: only elderly (65 years old or older)

Vinflunine is indicated in monotherapy for the treatment of elderly patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.

For this indication, competent medicine agencies globally authorize below treatments:

250-320 mg/m² once every 3 weeks

Route of admnistration

Intravenous

Defined daily dose

250 - 320 mg per m² of body surface area (BSA)

Dosage regimen

From 250 To 320 mg per m² of body surface area (BSA) once every 21 day(s)

Detailed description

The recommended dose is 320 mg/m² vinflunine as a 20 minute intravenous infusion every 3 weeks.

In case of WHO/ECOG performance status (PS) of 1 or PS of 0 and prior pelvic irradiation, the treatment should be started at the dose of 280 mg/m². In the absence of any haematological toxicity during the first cycle causing treatment delay or dose reduction, the dose will be increased to 320 mg/m² every 3 weeks for the subsequent cycles.

No age-related dose modification is required in patients less than 75 years old.

The doses recommended in patients of at least 75 years old are as follows:

  • in patients of at least 75 years old but less than 80 years, the dose of vinflunine to be given is 280 mg/m² every 3 weeks.
  • in patients 80 years old and above, the dose of vinflunine to be given is 250 mg/m² every 3 weeks.

For further cycles, the dose should be adjusted in the event of toxicities, as shown in the table below.

Dose adjustments due to toxicity in renal impaired or elderly patients:

ToxicityDose adjustment
(NCI CTC v 2.0)* Vinflunine initial dose of 280 mg/m²Vinflunine initial dose of 250 mg/m²
 First Event2° consecutive eventFirst Event2° consecutive event
Neutropenia Grade 4 (ANC <500/mm³) > 7 ημέρες250 mg/m²Definitive Treatment discontinuation225 mg/m²Definitive Treatment discontinuation
Febrile Neutropenia (ANC <1.000/mm³ and fever ≥38,5°C)
Mucositis or Constipation Grade 2 ≥ 5 days or Grade ≥ 3 any duration1
Any other toxicity Grade ≥ 3 (severe or life-threatening) (except Grade 3 vomiting or nausea2)

* National Cancer Institute, Common Toxicity Criteria Version 2.0 (NCI CTC v 2.0)
1 NCI CTC Grade 2 constipation is defined as requiring laxatives, Grade 3 as an obstipation requiring manual evacuation or enema, Grade 4 as an obstruction or toxic megacolon. Mucositis Grade 2 is defined as “moderate”, Grade 3 as “severe” and Grade 4 as “life-threatening”.
2 NCI CTC Grade 3 nausea is defined as no significant intake, requiring intravenous fluids. Grade 3 vomiting as ≥6 episodes in 24 hours over pretreatment; or need for intravenous fluids

Dosage considerations

Vinflunine should be administered by a 20-minute intravenous infusion and NOT be given by rapid intravenous bolus.

Active ingredient

Vinflunine

Vinflunine binds to tubulin at or near to the vinca binding sites inhibiting its polymerisation into microtubules, which results in treadmilling suppression, disruption of microtubule dynamic, mitotic arrest and apoptosis.

Read more about Vinflunine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.